Catalyst Pharmaceuticals, Inc. reaffirmed revenue guidance for the full-year 2024. For the year, the company expected total revenue in the range of $455 million and $475 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.17 USD | +0.37% | +1.89% | -3.81% |
05-30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
05-30 | Catalyst Pharmaceuticals Gets FDA Approval for Dose Increase in LEMS Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.81% | 1.9B | |
-2.29% | 89.38B | |
-3.95% | 37.92B | |
-13.07% | 32.04B | |
+63.05% | 26.03B | |
-22.14% | 14.14B | |
-7.96% | 12.88B | |
-9.33% | 11.77B | |
-46.33% | 10.85B | |
+5.77% | 8.92B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024